ADMP
Adamis Pharmaceuticals Corporation
Set alert
0.78 0.00 0.00%
0.75 Day range 0.7899
52-week range unavailable
- Open
- 0.75
- Prev close
- 0.775
- Mkt cap
- 6.29M
- Vol
- 119.48K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.75
- High
- 0.7899
- Forward P/E
- -29.25
- Beta
- 1.26
- Short ratio
- 0.57
- Inst. own
- 0.00%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 21, 2023
- 50-d avg
- 3.10
- 200-d avg
- 9.63
- 1y target
- 0.00
Key statistics
- Market cap
- 6.29M
- Enterprise value
- 2.86M
- Trailing P/E
- 0.00
- Forward P/E
- -29.25
- PEG ratio
- 0.00
- Price / sales
- 1.24
- Price / book
- 0.00
- EPS (TTM)
- -11.20
- Beta
- 1.26
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 5.05M
- Revenue growth
- 25.90%
- Free cash flow
- -7.86M
- Total cash
- 3.10M
- Total debt
- 380.51K
- Return on equity
- -784.96%
- Shares outstanding
- 2.66M
- Short % of float
- 2.67%
- 50-day average
- 3.10
- 200-day average
- 9.63
Analyst view
Consensus: hold
Hold
Price target (mean) 0.00
Ratings (0m) 3 3 buy · 0 hold · 0 sell
- Strong buy0
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 21, 2023
Expected Aug 21, 2023. Consensus EPS estimate 0.00.
Financials — quick view
ADMP Revenue — quarterly 6.95K
ADMP Net income — quarterly -8.57M
ADMP EPS — quarterly -3.40
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 21, 2023 | Jun 1, 2023 | 0.00 | — | — | — |
| May 15, 2023 | Mar 1, 2023 | 0.00 | — | — | — |
| Mar 16, 2023 | Dec 1, 2022 | 0.00 | — | — | — |
| Nov 14, 2022 | Sep 1, 2022 | 0.00 | — | — | — |
| Aug 10, 2022 | Jun 1, 2022 | -2.80 | — | — | — |
| May 16, 2022 | Mar 1, 2022 | -2.10 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 13, 2020 | Maxim Group | up | Hold | Buy |
| Nov 26, 2019 | Raymond James | down | Outperform | Market Perform |
| Nov 25, 2019 | Maxim Group | down | Buy | Hold |
| Jul 23, 2019 | B. Riley FBR | up | Sell | Neutral |
| Jul 16, 2019 | B. Riley | down | Neutral | Sell |
| Nov 12, 2018 | B. Riley FBR | down | Buy | Neutral |
About Adamis Pharmaceuticals Corporation
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine injectable pre-filled single dose syringe products for use in the emergency treatment of acute allergic reactions comprising anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company was founded in 2006 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Drug Manufacturers—Specialty & Generic
- Country
- United States
- Website
- adamispharmaceuticals.com
News
- Stocks That Hit 52-Week Lows On Thursday
- Adamis Pharmaceuticals Changes Name to DMK Pharmaceuticals to Reflect New Strategic Focus
- Stocks That Hit 52-Week Lows On Tuesday
- Adamis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
- Stocks That Hit 52-Week Lows On Wednesday
- Adamis Pharmaceuticals Announces Closing of $8.0 Million Public Offering
- Why Cummins Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
- Stocks That Hit 52-Week Lows On Wednesday
- Adamis Pharmaceuticals Announces Pricing of $8.0 Million Public Offering
- Why Aaron's Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Your note
Sign in to keep a note on ADMP — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BENEDICTO DAVID C. | Chief Financial Officer | Sale | Mar 17, 2022 | 39,875 |
| CARLO DENNIS J | Former | Conversion of Exercise of derivative security | May 24, 2022 | 692,459 |
| DANIELS KAREN K | Officer | Sale | Nov 17, 2020 | 149,242 |
| DESAI MEERA J. | Director | Stock Award(Grant) | May 24, 2023 | 3,138 |
| HOPKINS ROBERT O | Chief Financial Officer | Conversion of Exercise of derivative security | Feb 18, 2021 | 277,067 |
| MARGUGLIO DAVID J | Officer and Director | Sale | Mar 17, 2022 | 239,790 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 0.12% | 207,147 | 484.72K | Mar 30, 2023 |
| Vanguard Group, Inc. (The) | 0.05% | 92,629 | 216.75K | Mar 30, 2023 |
| Blackrock Inc. | 0.02% | 39,529 | 92.50K | Mar 30, 2023 |
| Geode Capital Management, LLC | 0.01% | 18,953 | 44.35K | Mar 30, 2023 |
| State Street Corporation | 0.00% | 6,791 | 15.89K | Mar 30, 2023 |
| Citadel Advisors Llc | 0.00% | 4,674 | 10.94K | Mar 30, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.73% | 4,096,010 | 9.58M | Dec 30, 2022 |
| Vanguard Extended Market Index Fund | 1.40% | 2,106,353 | 4.93M | Dec 30, 2022 |
| Fidelity Extended Market Index Fund | 0.52% | 783,328 | 1.83M | Feb 27, 2023 |
| Fidelity Total Market Index Fund | 0.13% | 200,206 | 468.48K | Feb 27, 2023 |
| Fidelity Series Total Market Index Fund | 0.11% | 167,252 | 391.37K | Feb 27, 2023 |
| Vanguard Institutional Index-Inst Total Stock Market Ind | 0.08% | 114,367 | 267.62K | Dec 30, 2022 |